Question 1

Should I use Saxenda or Ozempic for weight loss?

Accepted Answer

Neither is the ideal first choice if weight loss is the goal — Wegovy (semaglutide 2.4 mg weekly) or Zepbound (tirzepatide weekly) deliver substantially more weight reduction than either drug. Between these two: Saxenda is the only one of the pair FDA-labeled for obesity, and SCALE Obesity (Pi-Sunyer 2015, PMID 26132939) showed about 8% body weight loss at 56 weeks. Ozempic is labeled only for type 2 diabetes, but off-label prescribing produces roughly 6-7% loss in non-diabetic adults. The head-to-head STEP-8 trial (Rubino 2022, PMID 35015037) compared semaglutide 2.4 mg (the Wegovy dose, not Ozempic) to liraglutide 3.0 mg and showed -15.8% vs -6.4% — establishing that weekly semaglutide is mechanistically stronger than daily liraglutide for weight.

Question 2

Why doesn't Ozempic have an obesity label?

Accepted Answer

Novo Nordisk submitted semaglutide for obesity under a separate brand — Wegovy — at a higher 2.4 mg weekly dose, based on the STEP program (STEP-1 PMID 33567185). The FDA approves indications brand-by-brand and dose-by-dose, so the Ozempic NDA (capped at 2 mg weekly for type 2 diabetes) was never amended to include chronic weight management. The molecule is identical; the regulatory paperwork differs. Off-label prescribing of Ozempic for weight loss is common but typically uninsured because payers require the FDA-labeled indication.

Question 3

Can I get Ozempic for weight loss off-label?

Accepted Answer

Yes, clinicians can prescribe Ozempic off-label for weight loss, but insurance coverage is unlikely. Commercial plans almost universally require a documented type 2 diabetes diagnosis (A1C ≥6.5%) for Ozempic to be approved, and the NovoCare savings card explicitly excludes off-label use and cash-paying patients. Expect retail cash prices around $998 per month if you self-pay. If weight loss is your goal and you don't have T2D, Wegovy (same molecule, higher dose, labeled for obesity) is typically the more appropriate prescription.

Question 4

How does daily Saxenda compare to weekly Ozempic for adherence?

Accepted Answer

Once-weekly Ozempic has a meaningful adherence advantage. Real-world persistence studies of daily versus weekly GLP-1s consistently show higher 1-year continuation rates with weekly dosing — daily injections require 7x more injection events per year and more frequent titration reminders. Saxenda also requires a 5-step daily titration from 0.6 mg up to 3.0 mg over the first month to manage nausea, which is harder to maintain than Ozempic's 4-step weekly titration. If adherence is the limiting factor, weekly dosing typically wins.

Question 5

Will my T2D + obesity diagnosis cover both drugs?

Accepted Answer

Usually no — most commercial and Medicaid plans cover one GLP-1 per patient, even with both diagnoses. For patients with type 2 diabetes plus obesity, the typical pathway is to start with a T2D-labeled GLP-1 (Ozempic) because the T2D benefit is broader and the cardiovascular outcome data from SUSTAIN-6 (Marso 2016 NEJM, PMID 27633186, MACE -26%) is the only labeled CV-risk-reduction indication between these two. Saxenda's CV data comes from LEADER (Marso 2016 NEJM, PMID 27295427) but that trial used the 1.8 mg T2D dose (sold as Victoza), not the 3.0 mg obesity dose. Stacking both is rare; switching from Ozempic to Wegovy is more common than adding Saxenda on top.

Question 6

Is Saxenda approved for teenagers?

Accepted Answer

Yes. Saxenda is FDA-approved for adolescents ages 12-17 with obesity (defined as BMI corresponding to ≥30 kg/m² on adult growth charts) based on a 56-week pediatric trial. Ozempic is approved only for adults aged 18 and older. If you are looking for a labeled GLP-1 for an adolescent patient, Saxenda is currently the only one of this pair that qualifies — Wegovy is also approved down to age 12 for obesity and is generally preferred when available.

Field	Saxenda	Ozempic
FDA-approved indication	Chronic weight management (obesity)	Type 2 diabetes; CV risk reduction in T2D + established CVD
Active ingredient & mechanism	Liraglutide — GLP-1 receptor agonist	Semaglutide — GLP-1 receptor agonist
Route & frequency	Subcutaneous injection, once daily (3.0 mg target)	Subcutaneous injection, once weekly (0.25 → 2 mg titration)
Weight loss (pivotal data)	-8.0% body weight / 56 wk (SCALE Obesity, 3.0 mg)	~6-7% off-label in non-T2D (no obesity RCT); STEP-8 sema 2.4 mg -15.8% vs lira 3.0 mg -6.4%
Head-to-head (STEP-8, 68 wk)	-6.4% body weight (liraglutide 3.0 mg daily)	-15.8% body weight (semaglutide 2.4 mg weekly — Wegovy dose, not Ozempic)
Cardiovascular outcome	LEADER: MACE -13% in T2D (lira 1.8 mg, not 3.0 mg obesity dose)	SUSTAIN-6: MACE -26% in T2D (HR 0.74, p=0.02 superiority)
Cash price & manufacturer program	~$1,349/mo retail; no Novo manufacturer cash-pay program for Saxenda	~$998/mo retail; NovoCare savings card limited to commercial T2D
Insurance & prior auth	Obesity benefit + BMI ≥30 (or ≥27 + comorbidity); frequently excluded by commercial plans	T2D diagnosis + A1C ≥6.5% + metformin trial; broadly covered
Pediatric approval	Adolescents ages 12-17 with BMI ≥30 equivalent (since Dec 2020)	Adults only (≥18 years)

Saxenda vs Ozempic (2026): Daily Liraglutide vs Weekly Semaglutide

The verdict

Side-by-side comparison

Frequently asked questions